Core Viewpoint - Yuanxu Intelligent Medical Technology (Xiamen) Co., Ltd. has been established with a registered capital of 10 million yuan, focusing on various applications in the artificial intelligence sector [1] Company Summary - The company is wholly owned by Xiangyu Medical [1] - Its business scope includes artificial intelligence industry application system integration services, research and development of intelligent robots, sales of intelligent robots, sales of artificial intelligence hardware, and services for the artificial intelligence innovation and entrepreneurship platform [1]

Core Viewpoint - The demand for medium-frequency therapeutic devices in China is significantly increasing due to the aging population and the growing need for postoperative rehabilitation and chronic disease treatment, with a notable rise in market demand driven by enhanced health awareness among the public [1][7]. Market Overview - The medium-frequency therapeutic device, also known as low-frequency modulated medium-frequency therapeutic device, operates on the principle of medium-frequency electrotherapy, which is effective in disease treatment, pain relief, and rehabilitation care [1][5]. - The total procurement volume of medium-frequency therapeutic devices in China is projected to reach 6,745 units in 2024, representing a year-on-year increase of 37.26%, with a total procurement amount of 0.76 billion yuan, up 1.33% year-on-year [1][7]. Market Policy - The Chinese government emphasizes the development of the medical device industry, including medium-frequency therapeutic devices, through various policies aimed at regulating market order, ensuring product quality, and safeguarding patient safety [4][5]. Industry Chain - The upstream of the medium-frequency therapeutic device industry includes suppliers of electronic components such as control chips and power amplifiers, while the midstream involves R&D, design, and production [5]. - The downstream demand structure shows that medical institutions account for over 50% of the demand, with orthopedic and neurological rehabilitation being the core application areas [5][6]. Competitive Landscape - The market concentration for medium-frequency therapeutic devices in China is high, with the top five companies holding a market share of 55.66% as of the first half of 2025. Xiangyu Medical leads with a market share of 15.39% [8]. - Xiangyu Medical reported a total revenue of 744 million yuan in 2024, with 67.79% coming from rehabilitation therapy equipment [9]. - Beiyikang, another key player, achieved a revenue of 115 million yuan in the first half of 2025, with 84.98% from rehabilitation technology products [10]. Development Trends - The future of medium-frequency therapeutic devices will focus on smart technology integration, including AI algorithms for personalized treatment and IoT for data sharing and remote monitoring [11]. - The application scenarios for these devices are expected to expand beyond traditional medical settings to include sports rehabilitation and wellness, targeting specific user groups such as office workers and fitness enthusiasts [11].

Core Viewpoint - Neihuang County is committed to becoming a technology-driven and industry-strong county, focusing on three major industrial clusters: ceramics, rehabilitation equipment, and agricultural machinery, aiming for high-quality development and advanced manufacturing in Central China [1][2][3] Group 1: Ceramics Industry - Neihuang County's ceramics industry park houses 12 key ceramic enterprises and 20 modern production lines, with an annual output of 46.5 million square meters of tiles, making it the largest and most diverse ceramic production base in the Central China region [1] - The county has invested 1.33 billion yuan in upgrading environmental facilities, emphasizing "intelligent transformation and green upgrading" as key strategies for industry transition [1][2] Group 2: Rehabilitation Equipment - The rehabilitation equipment sector has established a complete industrial chain with 62 upstream and downstream enterprises, supported by a total investment of 2.5 billion yuan in the rehabilitation equipment industrial park [2] - A national-level testing center for rehabilitation medical devices has been established, equipped with over 1,000 advanced devices capable of conducting more than 2,000 tests, providing one-stop testing services for enterprises [2] Group 3: Agricultural Machinery - Neihuang County is actively integrating into the provincial "7+28+N" key industrial chain system to cultivate new growth points in agricultural machinery manufacturing [2] - A rapidly developing agricultural machinery industrial park with a total investment of 3 billion yuan is expected to produce 50,000 tractors annually, with projects like large combine harvester assembly and new seeders already in production [2] Group 4: Technological Innovation - The county is focusing on high-quality development and new productive forces as core engines for economic advancement, aligning with strategic directives from higher-level government meetings [3] - The county aims to enhance the synergy between technological innovation and industrial innovation to accelerate the growth and vitality of new productive forces [3]

人民财讯11月30日电，11月29日，翔宇医疗与湖南省康复医学会、邵阳学院附属第一医院康复医学科共 建的脑机接口临床研究与转化创新分中心启动仪式在医院多功能厅顺利举行。目前，翔宇医疗脑机接口 —上下肢主被动康复训练仪、脑机接口—吞咽神经和肌肉电刺激仪等系列设备已进入医院病房。 转自：证券时报 ...

Core Viewpoint - The company is cautiously advancing its investment and acquisition efforts in the rehabilitation medical device industry, focusing on external growth through integration and partnerships, despite recent declines in revenue and profit [1][2][3] Group 1: Financial Performance - Since its listing in 2021, the company's revenue and net profit peaked in 2023 but began to decline thereafter, with a projected revenue of 744 million yuan in 2024, down 0.17% year-on-year, and a net profit of 103 million yuan, down 54.68% year-on-year [2] - For the first three quarters of 2025, the company reported a revenue of 537 million yuan, a year-on-year increase of 6.00%, but a net profit of 44 million yuan, down 40.09% year-on-year, primarily due to increased sales and R&D expenses [3] Group 2: Research and Development Focus - The company is increasing its R&D investment, with a total of 140 million yuan in R&D for the first three quarters of 2025, a year-on-year increase of 34.69%, representing 26.11% of revenue, up 5.56 percentage points year-on-year [3] - The company is focusing its R&D efforts on rehabilitation robots and brain-computer interface technologies, with significant projects approved in the field of elderly care, including a specialized bathing robot [4][5] Group 3: Strategic Projects - The company is leading a project for the development and application of a specialized bathing robot for home care, aiming to improve safety, comfort, and cleanliness for bedridden elderly individuals [4] - The company has established a brain-computer interface laboratory and is integrating this technology into its rehabilitation products, which is expected to enhance recovery outcomes for patients [5]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688626 证券简称：翔宇医疗公告编号：2025-056 河南翔宇医疗设备股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （一）股东大会召开的时间：2025年11月24日 （二）股东大会召开的地点：河南省安阳市内黄县帝喾大道中段公司会议室 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： ■ 注：公司表决权数量不含截至股权登记日公司已回购股份的数量。 （四）表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，由董事长何永正先生主持，会议以现场投票和网络投票相结合的方式 进行表决。本次会议的召集、召开及表决方式符合《公司法》、《证券法》、《公司章程》等的规定。 （五）公司董事、监事和董事会秘书的出席情况 1、公司在任董事5人，现场出席5人； 2、公司在任监事 ...

证券日报网讯 11月24日晚间，翔宇医疗发布公告称，公司于2025年11月24日召开职工代表大会，同意 选举李治锋先生为公司第三届董事会职工代表董事，任期自本次职工代表大会选举通过之日起至第三届 董事会届满之日止。 （文章来源：证券日报） ...

Core Viewpoint - The establishment of the Brain Science and Brain-Computer Interface Innovation and Transformation Center by Xiangyu Medical and Xiangyang First People's Hospital aims to provide integrated solutions for patients with neurological diseases, breaking down disciplinary barriers and connecting intervention and rehabilitation technologies [1] Group 1 - The center integrates key disciplines such as neurosurgery, neurology, and rehabilitation medicine [1] - It focuses on providing solutions for conditions like Parkinson's disease, stroke, spinal cord injuries, and orthopedic rehabilitation [1] - The center addresses the diagnostic and treatment needs of patients at different stages of neurological diseases [1]

证券代码：688626 证券简称：翔宇医疗 公告编号：2025-057 河南翔宇医疗设备股份有限公司 关于选举第三届董事会职工代表董事的公告 特此公告。 河南翔宇医疗设备股份有限公司董事会 2025 年 11 月 25 日 附件： 第三届董事会职工代表董事简历 李治锋，男，汉族，1986 年出生，本科学历，材料物理专业，中国国籍， 无境外永久居留权。2007 年 7 月至 2014 年 4 月任安阳市科能电站锅炉部件有限 公司总经理助理；2014 年 5 月至 2021 年 7 月先后任公司人力资源部主管、行政 部部长；2021 年 7 月至今任公司研发中心副总监兼技术市场部部长、保密办主 任，2018 年 12 月至 2025 年 11 月任公司监事会主席。 截至目前，李治锋先生未持有本公司股份，与公司其他董事、高级管理人员、 实际控制人及持股 5%以上的股东不存在关联关系；不存在《公司法》等法律法 规及其他有关规定不得担任公司董事的情形，不存在被中国证监会采取市场禁入 措施的情形，不存在被证券交易所公开认定为不适合担任公司董事的情形；未受 到中国证监会行政处罚，未受到证券交易所公开谴责或者三次以上通报批评 ...

证券代码：688626 证券简称：翔宇医疗 公告编号：2025-056 河南翔宇医疗设备股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 2、 公司在任监事3人，现场出席3人； 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 11 月 24 日 （二） 股东大会召开的地点：河南省安阳市内黄县帝喾大道中段公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 74 | | --- | --- | | 普通股股东人数 | 74 | | 2、出席会议的股东所持有的表决权数量 | 114,629,702 | | 普通股股东所持有表决权数量 | 114,629,702 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 73.4476 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例 ...